First U.K. Patient Receives Trial Drug as Treatment for Covid-19
September 27 2020 - 7:30PM
Dow Jones News
By Adriano Marchese
The first U.K. patient has been treated with an experimental
drug for severe lung disease related to Covid-19, the Manchester
University NHS Foundation Trust said Monday.
The patient is part of the Oscar study conducted by U.K.
pharmaceutical giant GlaxoSmithKline PLC, set up to investigate
whether one of its pipeline drugs, Otilimab, can help reduce the
effects of the so-called cytokine storm--a severe immune reaction
where the body starts to attack its own cells--which was found to
occur in some hospitalized Covid-19 patients.
The drug is a monoclonal antibody that was already in late-stage
clinical trials and was originally considered as a potential new
treatment for rheumatoid arthritis.
The patient is being treated at the Manchester Royal Infirmary,
part of the Manchester University NHS Foundation Trust, and was
recruited to the study on Sept. 11.
The Oscar study, which stands for Otilimab in Severe
Covid-19-Related Disease, is sponsored and funded by
GlaxoSmithKline and is one of several studies that received the
urgent public-health research status by the U.K.'s Department of
Health and Social Care.
The study is planned to be extended to more hospitals across the
U.K., the Manchester University NHS Foundation Trust said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
September 27, 2020 19:15 ET (23:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024